Astex Pharmaceuticals, Inc. Message Board
-
Dacogen and Ovarian cancer
In the A-Day presentation, they mention dac and ovarian cancer. The response rates are excellent. In 70% of pts they saw response rates. This is why they went after Ovarian cancer with sgi-110. Med PFS with dac was 309 Days.
AT13387 hits multiple targets that Abiraterone misses. This combination could reverse resistance. The other key both these drugs can be given for years and even during progression.
At ACCR they will present 11 abstracts
5 with sgi-110
1 At13387
1 Amuvatinib
1AT9283
1 AT13148
1 LEE011 by novartis
1 IAP PreclinicalSentiment: Strong Buy
-
"The response rates are excellent."
Hate,
Certainly positive news. Unfortunately, we don't have enough "believers" buying the stock. Hopefully, this will change. With the cash position of the company, and the potenial in the pipeline, this company is way too cheap in my opinion.
regards,
Silverold- 1 Reply to silverold
-
I meant "potential." ( Maybe I better start checking my posts for spelling errors.)
-
Dumb and dumber have spoken. Same brain farts daily. Watch and learn.
Sentiment: Strong Buy
- 1 Reply to kyjellie
-
I Am Watching and Learning!
-
Yawn, wake me up when they have something ready to sell. I am tired of hearing about the comics. Endless papers of what if and “just around the corner”. The point is they have NEVER EVER produce a SINGE drug ready for sale.
Hey, maybe next quarter!- 1 Reply to thinkabout1120
-
Now you know how we feel when you post THINK. That's actually the one thing you don't do is think. You thought selling at 2.31 was smart. If they had one single drug ready for sale, the share price would be $10. Only a duffice would post such gargle.
Sentiment: Strong Buy
-
Google dacogen and ovarian cancer. Side effects will be much lower than dacogen in the sgi-110 trial. Dr. Brown stated this several times.
Sentiment: Strong Buy
- 1 Reply to kyjellie
-
I understand the benefits of s110 but remember 5+ years of management hype to get it into the clinics. Another 5 years and the 130 mil is gone, the 75 mil yearly Dacogen revenues will be gone but management bonuses and stock options continue.
-